<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-43329" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Rocuronium</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jain</surname>
            <given-names>Ankit</given-names>
          </name>
          <aff>Augusta University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Wermuth</surname>
            <given-names>Harrison R.</given-names>
          </name>
          <aff>Michigan State University College of Human Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dua</surname>
            <given-names>Anterpreet</given-names>
          </name>
          <aff>Augusta University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Singh</surname>
            <given-names>Karampal</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Maani</surname>
            <given-names>Christopher V.</given-names>
          </name>
          <aff>US Army; USUHS; BAMC; UTHSCSA; UIW</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ankit Jain declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Harrison Wermuth declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anterpreet Dua declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Karampal Singh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Christopher Maani declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-43329.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Rocuronium, a paramount non-depolarizing neuromuscular blocker, is utilized in clinical settings for inducing muscle relaxation during surgical procedures and lung ventilation during elective and emergent scenarios. Recognized for its rapid onset and reversibility within its drug class, rocuronium offers distinct advantages. This program addresses the crucial aspects of rocuronium that are necessary for healthcare professionals to understand. Participants will gain insights into the drug's indications, mechanism of action, administration modalities, significant adverse effects, contraindications, toxicity profiles, and monitoring parameters.</p>
        <p>This program aims to enhance providers' proficiency in utilizing rocuronium for anesthesia-related interventions, fostering seamless collaboration within an interprofessional healthcare team. The goal is to empower healthcare providers with a profound understanding of rocuronium, enabling them to skillfully guide patient therapy in anesthesia, highlighting the critical role of informed decision-making and collaborative care for optimal patient outcomes in surgical and ventilatory settings.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate clinical scenarios warranting using rocuronium as a neuromuscular blocking agent during anesthesia and ventilation procedures.</p></list-item><list-item><p>Screen patients for factors affecting the&#x000a0;selection&#x000a0;of rocuronium, such as medical history, comorbidities, and potential drug interactions.</p></list-item><list-item><p>Implement safe and appropriate dosing strategies for rocuronium administration, ensuring precise timing and dosage following anesthesia induction protocols.</p></list-item><list-item><p>Assess patient responses to rocuronium, monitor neuromuscular blockade depth, and evaluate for adverse effects or complications during anesthesia and mechanical ventilation.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=43329&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=43329">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-43329.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Rocuronium is a non-depolarizing neuromuscular blocker widely used to produce muscle relaxation to help facilitate surgery and ventilation of the lungs in elective and emergent situations.&#x000a0;Rocuonium is one of many non-depolarizing neuromuscular blockers&#x000a0;available, but it has the advantage of being fast-acting and reversible.&#x000a0;</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>As an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation</p>
          </list-item>
          <list-item>
            <p>Provide skeletal muscle relaxation/paralysis to facilitate surgery</p>
          </list-item>
          <list-item>
            <p>Provide chest wall relaxation to facilitate mechanical ventilation in critically ill patients who are under adequate sedation</p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Provide a defasciculating dose to prevent fasciculations during depolarizing muscle paralysis to prevent myalgias.</p>
          </list-item>
          <list-item>
            <p>Prevent shivering in patients post-cardiac resuscitation after the return of spontaneous circulation during therapeutic hypothermia.</p>
          </list-item>
        </list>
        <p>It is vital to ensure that the patients who receive a muscle relaxant like rocuronium are adequately sedated to prevent the risk of awareness. A patient can be paralyzed but awake&#x000a0;and&#x000a0;unable to show motor signs of awareness.</p>
      </sec>
      <sec id="article-43329.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Non-depolarizing neuromuscular blockers work at the site of nicotinic neuromuscular junction by acting on the synapse. A synapse is a specialized area where the prejunctional nerve ending interacts with a highly folded postjunctional part of the skeletal membrane. These pre- and post-junctional sites have a higher concentration of acetylcholine (Ach) and nicotinic acetylcholine receptors (nAchR).</p>
        <p>Usually, when an electrical impulse reaches the prejunctional nerve terminal, calcium influx causes a release of Ach ligands, which then interact with the nicotinic acetylcholine receptors located at the postjunctional membrane, to cause changes in the electrical permeability of the membrane, specifically sodium, and potassium. This rapid movement of ions causes a decrease in the transmembrane potential to reach threshold potential, generating an action potential that travels across the muscle membrane and causes muscular&#x000a0;contraction.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:&#x000a0;</bold>Rocuronium is poorly absorbed when taken orally.&#x000a0;Following IV administration, the drug's absorption is essentially complete.</p>
        <p><bold>Distribution:&#x000a0;</bold>Rocuronium distributes into extracellular space. Researchers have measured&#x000a0;the central volume of distribution of rocuronium at&#x000a0;78 &#x000b1; 24 mL/kg&#x000a0;in patients with normal liver function.<xref ref-type="bibr" rid="article-43329.r1">[1]</xref></p>
        <p><bold>Metabolism:&#x000a0;</bold>Rocuronium is hepatically metabolized&#x000a0;to a less active metabolite, 17-desacetyl-rocuronium, and is also hepatically eliminated.</p>
        <p><bold>Elimination:&#x000a0;</bold>Rocuronium has a half-life of 1.4 to 2.4 hours. The drug is secreted in the bile and urine.</p>
      </sec>
      <sec id="article-43329.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Nondepolarizing drugs like rocuronium are quaternary ammonium compounds, which are intermediately acting, highly ionized drugs administered intravenously under controlled conditions by anesthesiologists and other critical care providers after ensuring that the patient is under the effects of anesthesia. The administration dose can be decided based on the clinical indication versus patient characteristics. Rocuronium does not undergo metabolism into active metabolites and has minimal lipid solubility. Therefore, these drugs do not pass the blood-brain&#x000a0;barrier, placental barrier, and other lipid membrane barriers.<xref ref-type="bibr" rid="article-43329.r2">[2]</xref>&#x000a0;If given orally, rocuronium has no effects on the central nervous system, impact on the fetus, minimal renal reabsorption, and ineffective absorption. Rocuronium is primarily excreted unchanged in bile and has around 30% renal excretion. Factors like hypothermia, hypovolemia, concomitant volatile agents, and renal and hepatic diseases prolong the effects of rocuronium.</p>
        <p>Rocuronium is an intermediate-acting nondepolarizing neuromuscular blocker with an ED95 of 0.3 mg/kg. At a dosing range of 0.6 to 1.2 mg/kg, intubating conditions can be reached in 1 to 2 minutes, with effects lasting until 20 to 35 minutes. Higher doses, like 1.0 to 1.2 mg/kg, can provide intubating conditions similar to succinylcholine&#x000a0;with a short onset time&#x000a0;of approximately 1 minute. However, that comes with a duration of action similar to longer-acting nondepolarizing drugs like pancuronium.</p>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p>Endotracheal intubation: 0.6 mg/kg/dose IV for a single dose.</p>
        <p>Rapid sequence intubation: 1 to 1.2 mg/kg/dose IV for a single dose.</p>
        <p>Neuromuscular blockade induction:&#x000a0;0.6 mg/kg/dose IV for a single dose.</p>
        <p>Neuromuscular blockade maintenance: 0.1 to 0.2 mg/kg/dose IV as needed.</p>
        <p>
<bold>Special Patient Population</bold>
</p>
        <p><bold>Hepatic impairment:</bold> Dosing in hepatic impairment is undefined; caution is advised.<xref ref-type="bibr" rid="article-43329.r3">[3]</xref></p>
        <p><bold>Renal impairment:</bold> No dose adjustment is necessary in patients with renal impairment.</p>
        <p><bold>Pregnant females:</bold> Rocuronium can be used during pregnancy, particularly in the 2nd and 3rd trimesters; limited human data indicates no risk of fetal harm.<xref ref-type="bibr" rid="article-43329.r4">[4]</xref></p>
        <p><bold>Breastfeeding females:</bold> Clinicians should weigh the risks vs benefits in patients who are breastfeeding; there is no known risk of infant harm based on limited human data. No data is available to assess the drug's effect on milk production.</p>
        <p><bold>Pediatric patients:</bold>&#x000a0;<bold>dosing</bold></p>
        <p>Neuromuscular blockade induction:&#x000a0;0.6 mg/kg/dose IV for a single dose.</p>
        <p>Neuromuscular blockade maintenance:</p>
        <list list-type="bullet">
          <list-item>
            <p>Younger than 17 years: isoflurane/nitrous oxide anesthesia; 0.1 to&#x000a0;0.2 mg/kg/dose IV for a single dose.</p>
          </list-item>
          <list-item>
            <p>Three months to 14 years: halothane anesthesia; 0.075 to&#x000a0;0.125 mg/kg/dose IV as needed.</p>
          </list-item>
        </list>
        <p><bold>Older patients:&#x000a0;</bold>Rocuronium elimination is reduced in older patients, leading to prolonged duration.&#x000a0;This prolongation&#x000a0;represents a nearly&#x000a0;2-fold increase, from 31 minutes in younger patients to 51 minutes in older patients.&#x000a0;Therefore, extra dose&#x000a0;administration in older patients requires care and should only be administered after the train-of-four response reappears.<xref ref-type="bibr" rid="article-43329.r5">[5]</xref></p>
      </sec>
      <sec id="article-43329.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Allergic Reactions</bold>
</p>
        <p>Although there have been reports of cardiovascular adverse effects with non-depolarizing neuromuscular agents like mivacurium and atracurium, rocuronium is very cardiac stable and has no impact on heart rate or blood pressure. Rocuronium has been implicated in multiple IgE-induced anaphylaxes in the perioperative setting, and&#x000a0;one article&#x000a0;cites the incidence of around 1 in 2,500 patients.<xref ref-type="bibr" rid="article-43329.r6">[6]</xref>&#x000a0;After rocuronium administration, any patient who develops sudden cardiovascular collapse along with cutaneous symptoms of allergic reactions should come under suspicion for anaphylaxis. Common adverse events include transient hypotension, hypertension, and tachycardia.</p>
        <p>
<bold>Residual Neuromuscular Weakness</bold>
</p>
        <p>Residual neuromuscular blockade is a condition where the effects of the neuromuscular blocks do not completely reverse. The adverse effects of the residual neuromuscular blockade have been proven beyond doubt to increase postoperative morbidity and mortality.<xref ref-type="bibr" rid="article-43329.r7">[7]</xref>&#x000a0;The inability to completely reverse the effects of the neuromuscular blockade can result in increased risks of postoperative respiratory dysfunction, including hypoxia, the need for mechanical&#x000a0;ventilation, and an increase in the length of hospital stay.<xref ref-type="bibr" rid="article-43329.r8">[8]</xref></p>
        <p>
<bold>Critical Illness Myopathy and Polyneuropathy</bold>
</p>
        <p>Prolonged infusion of neuromuscular blockers can prolong skeletal muscle weakness due to the myopathy induced by critical illness in a subset of patients on steroids or who have multiple organ failure. The recommendation is&#x000a0;to keep the&#x000a0;duration of paralysis to less than 48 hours to prevent this complication.<xref ref-type="bibr" rid="article-43329.r9">[9]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Several drugs, including aminoglycosides, tetracyclines, vancomycin, clindamycin, lithium, procainamide, lidocaine, and other local anesthetics, beta-adrenergic blockers, potassium-depleting diuretics, general inhalation anesthesia, and succinylcholine may prolong the intensity and duration of paralytic action. This is not an exhaustive list.</p>
          </list-item>
          <list-item>
            <p>Patients receiving long-term phenytoin or carbamazepine may require higher infusion rates and experience reduced duration of action.</p>
          </list-item>
          <list-item>
            <p>ROcuemonium may be associated with QTc prolongation when administered with general anesthesia.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-43329.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The absolute contraindication to using rocuronium would be a documented allergic reaction to the drug. Rocuronium should also not be given to any patient who is not sedated or not under the influence of anesthesia to avoid the risk of awareness. Rocuronium should not be used as an infusion to prevent critical illness myopathy and polyneuropathy. Rocuronium should not be used in patients with hepatic dysfunction as it will prolong its effects by delaying elimination. Using sugammadex, rocuronium can also be used cautiously in these clinical situations.<xref ref-type="bibr" rid="article-43329.r10">[10]</xref></p>
      </sec>
      <sec id="article-43329.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The effects of the neuromuscular blockade are assessable by evaluating a mechanically evoked response to an electrical stimulation using a peripheral nerve stimulator. The Anesthesia Patient Safety Foundation (APSF) strongly encourages using peripheral nerve stimulators to monitor the depth of neuromuscular blockade during surgery and after reversal by the reversal agent to confirm and rule out any residual neuromuscular blockade.<xref ref-type="bibr" rid="article-43329.r11">[11]</xref></p>
        <p>Routinely,&#x000a0;2 sites are used for peripheral nerve&#x000a0;stimulation: the distal forearm, where the ulnar nerve is stimulated using&#x000a0;2 electrodes placed on the anatomical path of the ulnar nerve to stimulate the adductor pollicis muscle of the hand, and around the eyes on the forehead to stimulate the facial nerve and orbicularis oculi muscle. The peripheral nerve stimulator can provide an electrical current of specific strength and duration to create a stimulation pattern. A train-of-four (TOF) is most commonly used to evaluate the amount of muscle contraction.</p>
        <p>Other types of stimulation include a single twitch response, double burst stimulation, tetany, and post-tetanic stimulation. In a TOF stimulation,&#x000a0;4 electrical stimulations at 2Hz are delivered every 0.5 sec, and the twitch height response of the fourth twitch is compared to the first twitch. In patients under the effect of rocuronium and other nondepolarizing&#x000a0;neuromuscular blocking drugs, the fourth twitch response is smaller than the first due to the depletion of Ach released on successive stimulation. This leads to calculating the TOF ratio and fade, a hallmark of nondepolarizing neuromuscular blockade. Loss of 2 twitches out of&#x000a0;4 is considered adequate for surgical anesthesia. If all&#x000a0;4 twitches are lost, more muscle relaxants should not be administered until some twitches are recovered. A TOF ratio of 0.7&#x000a0;to 0.9 is considered adequate for complete reversal.<xref ref-type="bibr" rid="article-43329.r12">[12]</xref></p>
      </sec>
      <sec id="article-43329.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Reversal of rocuronium-induced paralysis is possible with the use of&#x000a0;2 subgroups of drugs.<xref ref-type="bibr" rid="article-43329.r13">[13]</xref></p>
        <p>
<bold>Anticholinesterases</bold>
</p>
        <p>Drugs like neostigmine and rarely edrophonium and pyridostigmine have been the cornerstone of reversing neuromuscular blockade. Neostigmine is an anticholinesterase drug that prevents the metabolism of Ach in the synapse by blocking the action of cholinesterase, increasing the level of Ach in the synaptic cleft, and overcoming the neuromuscular blockade of non-depolarizing drugs like rocuronium. The typical dosing depends on the amount of neuromuscular blockade monitored by the TOF response to the peripheral nerve stimulator. If no twitches are visible in response to TOF, the administration of neostigmine is not recommended.&#x000a0;Examiners should wait for the twitch response to occur before administering neostigmine. If less than&#x000a0;2 twitches are present, 0.07 mg/kg of neostigmine is recommended along with an anticholinergic to prevent the adverse effects of cholinergic drugs like glycopyrrolate or atropine. If 3 or 4 twitches are present, 0.04 mg/kg of neostigmine is recommended with appropriate anticholinergic drugs.<xref ref-type="bibr" rid="article-43329.r14">[14]</xref></p>
        <p>
<bold>Sugammadex</bold>
</p>
        <p>A novel gamma-cyclodextrin molecule that encapsulates steroidal neuromuscular blockers like rocuronium and vecuronium has been extensively used in Europe before being approved recently in the US. The drug's&#x000a0;novel mechanism of action produces a complete reversal of neuromuscular blockade by encapsulating rocuronium and preventing&#x000a0;the interaction of rocuronium at the neuromuscular junction. Suggamedex additionally has some affinity in reversing Vecuronium and Pancuronium. Since&#x000a0;rocuronium does not work by interacting with cholinesterase, it produces no cardiac adverse effects&#x000a0;and can be safely used at any level of neuromuscular blockade. The dosing is based on the depth of neuromuscular blockade. If there are no twitches and the reversal is necessary after an intubating dose of rocuronium, then it is recommended&#x000a0;to use a 16 mg/kg dose. If there are no twitches to TOF, but there are&#x000a0;1 to&#x000a0;2 post-tetanic&#x000a0;responses, a 4 mg/kg dose should be used. If&#x000a0;4 twitches are present to TOF, then a 2 mg/kg dose can be used. The suggamadex-NMB complex is eliminated through 75% biliary clearance and 25% biliary clearance and excreted via the urine at 65&#x000a0;to 97%. Additionally, a female who takes hormonal contraceptives should be counseled on using a backup method for contraception within&#x000a0;7 days of its administration.<xref ref-type="bibr" rid="article-43329.r15">[15]</xref></p>
      </sec>
      <sec id="article-43329.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Proper use of neuromuscular blocking agents by the anesthesiologist, emergency department physician, intensivist, anesthesia nurse, and critical care specialists is paramount. Residual neuromuscular weakness is recognized&#x000a0;as a common problem in the post-anesthesia care unit (PACU), where at least 20% to 40% of patients can be shown to have objective evidence of residual weakness.<xref ref-type="bibr" rid="article-43329.r16">[16]</xref>&#x000a0;Current evidence suggests that routine monitoring of neuromuscular blockades is not performed regularly on each patient, and subjective assessment of muscle strengths like sustained head-lift and handgrips are unreliable markers of a complete reversal of neuromuscular blockade. The only objective method to ensure patient safety and a complete reversal is the TOF ratio greater than 0.9. Sugammadex&#x000a0;was introduced in 2008 worldwide, and in 2015 in the USA, reliable and consistent literature supports the safety and reliability of complete reversal of neuromuscular blockade.<xref ref-type="bibr" rid="article-43329.r17">[17]</xref><xref ref-type="bibr" rid="article-43329.r18">[18]</xref><xref ref-type="bibr" rid="article-43329.r19">[19]</xref></p>
      </sec>
      <sec id="article-43329.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=43329&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=43329">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/43329/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=43329">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-43329.s11">
        <title>References</title>
        <ref id="article-43329.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khalil</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>D'Honneur</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Duvaldestin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Slavov</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>De Hys</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gomeni</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis.</article-title>
            <source>Anesthesiology</source>
            <year>1994</year>
            <month>Jun</month>
            <volume>80</volume>
            <issue>6</issue>
            <fpage>1241</fpage>
            <page-range>1241-7</page-range>
            <pub-id pub-id-type="pmid">8010470</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43329.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richardson</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Raymond</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Sugammadex Administration in Pregnant Women and in Women of Reproductive Potential: A Narrative Review.</article-title>
            <source>Anesth Analg</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>130</volume>
            <issue>6</issue>
            <fpage>1628</fpage>
            <page-range>1628-1637</page-range>
            <pub-id pub-id-type="pmid">31283616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43329.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Magorian</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Caldwell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Segredo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Szenohradszky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gruenke</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease.</article-title>
            <source>Anesth Analg</source>
            <year>1995</year>
            <month>Apr</month>
            <volume>80</volume>
            <issue>4</issue>
            <fpage>754</fpage>
            <page-range>754-9</page-range>
            <pub-id pub-id-type="pmid">7893030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43329.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karahan</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>B&#x000fc;y&#x000fc;kf&#x00131;rat</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Binici</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Uyan&#x00131;ko&#x0011f;lu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Inceb&#x00131;y&#x00131;k</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aso&#x0011f;lu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Altay</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>The Effects of Rocuronium-sugammadex on Fetomaternal Outcomes in Pregnancy Undergoing Electroconvulsive Therapy: A Retrospective Case Series and Literature Review.</article-title>
            <source>Cureus</source>
            <year>2019</year>
            <month>Jun</month>
            <day>03</day>
            <volume>11</volume>
            <issue>6</issue>
            <fpage>e4820</fpage>
            <pub-id pub-id-type="pmid">31404381</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43329.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Athanassoglou</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pandit</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Neuromuscular blockade in the elderly patient.</article-title>
            <source>J Pain Res</source>
            <year>2016</year>
            <volume>9</volume>
            <fpage>437</fpage>
            <page-range>437-44</page-range>
            <pub-id pub-id-type="pmid">27382330</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43329.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takazawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mitsuhata</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mertes</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Sugammadex and rocuronium-induced anaphylaxis.</article-title>
            <source>J Anesth</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>290</fpage>
            <page-range>290-7</page-range>
            <pub-id pub-id-type="pmid">26646837</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43329.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pei</surname>
                <given-names>DQ</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>QH</given-names>
              </name>
            </person-group>
            <article-title>Grip strength can be used to evaluate postoperative residual neuromuscular block recovery in patients undergoing general anesthesia.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>98</volume>
            <issue>2</issue>
            <fpage>e13940</fpage>
            <pub-id pub-id-type="pmid">30633170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43329.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murphy</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Szokol</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Marymont</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Avram</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Vender</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit.</article-title>
            <source>Anesth Analg</source>
            <year>2008</year>
            <month>Jul</month>
            <volume>107</volume>
            <issue>1</issue>
            <fpage>130</fpage>
            <page-range>130-7</page-range>
            <pub-id pub-id-type="pmid">18635478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43329.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xi</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for intensive care unit-acquired weakness: A systematic review and meta-analysis.</article-title>
            <source>Acta Neurol Scand</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>138</volume>
            <issue>2</issue>
            <fpage>104</fpage>
            <page-range>104-114</page-range>
            <pub-id pub-id-type="pmid">29845614</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43329.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tobias</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Sugammadex: Applications in Pediatric Critical Care.</article-title>
            <source>J Pediatr Intensive Care</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>162</fpage>
            <page-range>162-171</page-range>
            <pub-id pub-id-type="pmid">32685243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43329.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McLean</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Diaz-Gil</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Farhan</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Ladha</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Kurth</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Eikermann</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Dose-dependent Association between Intermediate-acting Neuromuscular-blocking Agents and Postoperative Respiratory Complications.</article-title>
            <source>Anesthesiology</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>122</volume>
            <issue>6</issue>
            <fpage>1201</fpage>
            <page-range>1201-13</page-range>
            <pub-id pub-id-type="pmid">25919486</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43329.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fortier</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>McKeen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>de M&#x000e9;dicis</surname>
                <given-names>&#x000c9;</given-names>
              </name>
              <name>
                <surname>Warriner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Chaput</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pouliot</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Galarneau</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The RECITE Study: A Canadian Prospective, Multicenter Study of the Incidence and Severity of Residual Neuromuscular Blockade.</article-title>
            <source>Anesth Analg</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>121</volume>
            <issue>2</issue>
            <fpage>366</fpage>
            <page-range>366-72</page-range>
            <pub-id pub-id-type="pmid">25902322</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43329.r13">
          <label>13</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Clar</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Nondepolarizing Neuromuscular Blockers</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">30521249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43329.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Han</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Do</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Effects of magnesium sulphate on neostigmine-induced recovery from moderate neuromuscular blockade with rocuronium: a randomized controlled trial.</article-title>
            <source>Magnes Res</source>
            <year>2023</year>
            <month>Jun</month>
            <day>01</day>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>31</fpage>
            <page-range>31-39</page-range>
            <pub-id pub-id-type="pmid">37897256</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43329.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pirin&#x000e7; &#x0015e;a&#x0015f;&#x00131;o&#x0011f;lu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kendigelen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>T&#x000fc;t&#x000fc;nc&#x000fc;</surname>
                <given-names>A&#x000c7;</given-names>
              </name>
              <name>
                <surname>Kaya</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Reversal of Rocuronium-Induced Neuromuscular Blockade by Sugammadex Under Sevoflurane and Desflurane Anesthesia in Children.</article-title>
            <source>Eurasian J Med</source>
            <year>2023</year>
            <month>Oct</month>
            <volume>55</volume>
            <issue>3</issue>
            <fpage>173</fpage>
            <page-range>173-177</page-range>
            <pub-id pub-id-type="pmid">37909186</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43329.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brull</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kopman</surname>
                <given-names>AF</given-names>
              </name>
            </person-group>
            <article-title>Current Status of Neuromuscular Reversal and Monitoring: Challenges and Opportunities.</article-title>
            <source>Anesthesiology</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>126</volume>
            <issue>1</issue>
            <fpage>173</fpage>
            <page-range>173-190</page-range>
            <pub-id pub-id-type="pmid">27820709</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43329.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Staals</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Driessen</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Van Egmond</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>De Boer</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Klimek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Flockton</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Snoeck</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Train-of-four ratio recovery often precedes twitch recovery when neuromuscular block is reversed by sugammadex.</article-title>
            <source>Acta Anaesthesiol Scand</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>55</volume>
            <issue>6</issue>
            <fpage>700</fpage>
            <page-range>700-7</page-range>
            <pub-id pub-id-type="pmid">21574968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43329.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simonini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brogi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Calevo</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Carron</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Sugammadex for reversal of neuromuscular blockade in paediatric patients: A two-year single-centre retrospective study.</article-title>
            <source>Anaesth Crit Care Pain Med</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>38</volume>
            <issue>5</issue>
            <fpage>529</fpage>
            <page-range>529-531</page-range>
            <pub-id pub-id-type="pmid">30818070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43329.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jahr</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Hiruma</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Emaus</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>You</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Meistelman</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Sugammadex: A Scientific Review Including Safety and Efficacy, Update on Regulatory Issues, and Clinical Use in Europe.</article-title>
            <source>Am J Ther</source>
            <year>2015</year>
            <season>Jul-Aug</season>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>288</fpage>
            <page-range>288-97</page-range>
            <pub-id pub-id-type="pmid">25299637</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
